咯萘啶,Pyronaridine
1)Pyronaridine咯萘啶
1.Establishment of In vitro Microtest for Determining Sensitivity of Plasmodium falciparum to Pyronaridine;恶性疟原虫对咯萘啶敏感性的体外微量测试方法
2.Function and mechanism of pyronaridine: a new inhibitor of P-glycoprotein-mediated multidrug resistance;咯萘啶逆转肿瘤多药耐药及其作用机制(英文)
3.Combined administration of dihydroartemisinin and pyronaridine was given to the 32 cases of falciparum malaria cases with multi-drug resistance. 方法 双氢青蒿素、咯萘啶单用及伍用分别治疗 2 4、2 5和 32例恶性疟现症患者 ,分别于服药后第 14、2 1及 2 8天随访 ,以退热时间、原虫消失时间、复燃时间、复燃率、治愈率、配子体携带率、药物副作用发生率等为指标 ,以双氢青蒿素、咯萘啶标准疗法为对照 ,进行临床双盲试验 ,综合评估双氢青蒿素合并咯萘啶疗法。
英文短句/例句

1.Study on Pharmaconkinetics of Pyronaridine in Mice磷酸咯萘啶在小鼠体内的药动学过程
2.Study on the preparative procedure of inclusion compound of PND-HP-β-CD咯萘啶-羟丙基-β-环糊精包合物的制备
3.RP-HPLC determination of malaridine phosphate injection and its related substancesRP-HPLC法测定磷酸咯萘啶注射液含量及有关物质
4.The FIC obtained confirmed the synergism between PND and S/P.同时证明 ,咯萘啶与磺胺多辛 /乙胺嘧啶之间有协同效应。
5.OBSERVATION ON EFFICACY OF PYRONARIDINE PHOSPHATE AND IT COMBINED WITH DIHYDROARTEMISININ FOR TREATMENT OF MALARIA IN ERITREA, AFRICA磷酸咯萘啶及其合并双氢青蒿素治疗疟疾效果观察
6.The Study of a New Oral Preparation of Tumorous Multidrug-Resistance Inhibit Agent-Pyronaridine Phosphate;肿瘤多药耐药逆转剂—磷酸咯萘啶口服新剂型的研究
7.Pyrolysis Study of Pyrrole, Pyridine and 4-methyl Pyridine Compounds吡咯、吡啶及4-甲基吡啶的热解研究
8.A Simple Methods of Synthesis for Pyrrolo-Pyridines and Pyrrolo- quinolines;吡咯并吡啶(喹啉)类化合物的简易合成
9.EXPERIMENTAL INVESTIGATION ON THE OXIDATION RULES OF PYRIDINE AND PYRROLE AS MODEL COMPOUNDS模型化合物吡啶、吡咯氧化规律实验研究
10.Study on the Complex of Bi(Ⅲ) with PAN铋(Ⅲ)与1-(2-吡啶偶氮)-2-萘酚配合物的研究
11.CRYSTAL STRCTURE OF BIS(1,8-NAPHTHYRIDINE-N-OXIDE)COPPER(Ⅱ)NITRATE二(1,8-萘啶氮氧化物)合硝酸铜(Ⅱ)的晶体结构
12.Synthesis, Photochemical and Photophysical Properties of 1, 8-Naphthyridine Derivetives;1,8-萘啶衍生物的合成、光化学和光物理性质
13.Gene gyrA Mutation in Nalidixic acid-resistant Salmonella paratyphi A耐萘啶酸甲型副伤寒沙门菌gyrA基因突变研究
14.Photochemical properties of naphthalimide derivative grafted in MCM-41 by covalent bond键连在MCM-41哌啶萘酰亚胺的光化学性能
15.Solvent effect on hydroxyl-1,8 naphthyridine derivatives fluorescence properties溶剂效应对1,8-萘啶衍生物荧光性质的影响
16.Studies on 5,6-Substituted Derivatives of 1,10-Phenanthroline and Metal Complexes of Chelidamic Acid;5,6-二取代1,10-菲咯啉及4-羟基-2,6-吡啶二酸配合物的研究
17.Systhesis of Pyrrolyl Substituted 4,4'-Bipyridinium Derivatives and Used as Electrochromic Material;联吡啶基吡咯衍生物电致变色材料的合成与性质研究
18.Study on Synthesis、Characterization and Application of Transition-metal-Ploypyridine-Phenanthroline Fluorescent Probe for Nucleic Acids;过渡金属—多吡啶—菲咯啉类核酸荧光探针的合成、表征及应用研究
相关短句/例句

Malaridine疟乃停 ,磷酸咯萘啶
3)malaridine phosphate injection磷酸咯萘啶注射液
1.RP-HPLC determination of malaridine phosphate injection and its related substancesRP-HPLC法测定磷酸咯萘啶注射液含量及有关物质
4)naphthyridine[n?f'θiridin]萘啶
1.7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxyl.本文以氟乙酸甲酯和甲酸乙酯、氰乙酰胺为原料,经缩合、环合反应制得2,6-二羟基-5-氟菸腈,再经氯化、水解反应得到2,6-二氯-5-氟菸酸,该产物经酰化反应得到2,6-二氯-5-氟-吡啶-3-甲酰氯,再经取代、缩合、环合反应得到7-氯-1-环丙基-6-氟-1,4-二氢-4-氧代-1,8-萘啶-3-羧酸乙酯,再经哌嗪缩合、水解、酸化得到目标化合物。
2.Methods Based on several ARIs existed,three naphthyridine derivatives have been designed and synthesized via four steps of reaction,and the ALR2 activity of them three were tested.方法基于几种已存在的醛糖还原酶抑制剂的结构,经过4步反应,合成了三种萘啶衍生物,并对其进行体外ALR2活性测试。
3.A new way for synthesizing bromo-、chloro-naphthyridine was repord in this thsisi.采用新的路线合成溴代、氯代萘啶,以氨基吡啶为原料,利用氨基的强定位效应得到单取代的溴代、氯代氨基吡啶,再通过Skraup关环得到不同位置、单一取代的溴代、氯代萘啶。
5)naphthazole萘并吡咯
6)rolodine罗咯啶
延伸阅读

咯萘啶药物名称:磷酸咯萘啶英文名:Malaridine别名: 咯萘啶;疟乃停 ,磷酸咯萘啶外文名:Pyronaridine 适应症: 本品为我国创制的抗疟药物,其作用优于咯啶,主要能杀灭裂殖体,抗疟疗效显著。对氯奎有抗药性的病人亦有效。适用于治疗各种疟疾包括脑型疟和凶险疟疾的危重病人。 用量用法: 试用口服量:小儿总剂量为每千克体重24mg,分3次服。成人第1日服2次,每次0.3g,间隔4~6小时。第2、3日各服1次。 静滴:每次每千克体重3~6mg,加入5%葡萄糖液200~500ml中,于2~3小时左右滴毕。间隔6~8小时重复1次,12小时内总剂量相当于每千克体重12mg。 臀部肌注:每次每千克体重2~3mg,共给2次,间隔4~6小时。以上剂量均以盐基计。 注意事项: 1.口服后少数病例出现轻度腹痛、胃部不适。 2.肌注后局部有硬块,少数病人有头昏、恶心、心悸等不良反应。 3.严重心、肝、肾病者慎用。 规格: 肠溶片:每片含盐基100mg。注射液80mg(盐基)(2ml)。 类别:抗疟药